4107061066

Form PTO-1595 (Rev. 03-09) OMB No. 0651-0027 (exp. 03/31/2009)	U.S. DEPARTMENT OF COMMERCE United States Patent and Trademark Offic
RECORDATION FO	ORM COVER SHEET
	Se record the attached documents or the new address(es) below.
Name of conveying party(ies)	
1. Name of conveying party(ies,	2. Name and address of receiving party(ies)  Name: University of Maryland, Baltimore
University of Maryland Biotechnology Institute	Internal Address:
Additional name(s) of conveying party(ies) attached? Yes X No.  3. Nature of conveyance/Execution Date(s):	Street Address: 620 W. Lexington Street, 4th floor
Execution Date(s) April 1, 2010  Assignment Merger	
Security Agreement Change of Name Joint Research Agreement	City: Baltimore  State: Maryland
Government Interest Assignment Executive Order 9424, Confirmatory License	Country: <u>u.s.</u> Zip: <u>21201</u>
Other	Additional name(s) & address(es) attached?  Yes  No
4. Application or patent number(s):  A. Patent Application No.(s)	document is being filed together with a new application.  B. Patent No.(s)
09/637,652	6,479,466
Additional numbers att	
5. Name and address to whom correspondence concerning document should be mailed:	6. Total number of applications and patents involved:
Name: Gail Knott	7. Total fee (37 CFR 1.21(h) & 3.41) \$40.00
Internal Address: University of Maryland, Baltimore	
Office of Research and Development	X Authorized to be charged to deposit account
Street Address: 620 W. Lexington Street, 4th floor	Enclosed  None required (government interest not affecting title)
City: Baltimore	8. Payment Information
State: MD Zip: 21201	
Phone Number: 410-706-2380	_
Fax Number: 41-706-1066	Deposit Account Number 210684
Email Address: gknot001@umaryland.edu	Authorized User Name_Gail Knott

Documents to be recorded (including cover sheet) should be faxed to (571) 273-0140, or mailed to: Mail Stop Assignment Recordation Services, Director of the USPTO, P.O.Box 1450, Alexandria, V.A. 22313-1450

**Gall Knott** 

Name of Person Signing

PATENT REEL: 024678 FRAME: 0821

July 14, 2010 Date

Total number of pages including cover sheet, attachments, and documents:

9. Signature:

## PATENT ASSIGNMENT

THIS PATENT ASSIGNMENT is made as of the date of the last signature on the signature page ("Effective Date"), by and between UNIVERSITY OF MARYLAND BIOTECHNOLOGY INSTITUTE, having a principal place of business at 701 East Pratt Street, Suite 200, Baltimore, MD 21202 ("Assignor") and UNIVERSITY OF MARYLAND, BALTIMORE, by its Office of Commercial Ventures and Intellectual Property, 620 West Lexington Street, 4<sup>th</sup> Floor, Baltimore, Maryland 21201 ("Assignee"). Assignor and Assignee are each institutions of the University System of Maryland ("USM"), a public corporation and an instrumentality of the State of Maryland.

WHEREAS, the assets of Assignor are being transferred to various institutions of the USM; and

WHEREAS, the Institute of Human Virology ("IHV") was transferred to Assignee on July 1, 2007; and

WHEREAS, Assignor is the exclusive owner of all right, title, and interest in and to the patent(s) and patent application(s) identified in **Exhibit A** attached hereto; and

WHEREAS, Assignee desires to acquire all right, title, and interest in and to said patents and patent applications; and

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Assignor hereby assigns to Assignee all right, title, and interest to all intellectual property identified in Exhibit A attached hereto, and in any and all United States and/or international or foreign patent applications thereon, continuing patent applications thereon (including without limitation substitutions, divisionals, continuations, and continuations-in-part), patents or Letters Patent issued therefrom, and reissues, extensions, renewals, and reexaminations of such applications or patents (collectively, the "Patents and Patent Applications").

Such entire right, title, and interest in the Patents and Patent Applications are to be held and enjoyed by Assignee to the same extent as they would have been held and enjoyed by Assignor had this Assignment not been made, to the full end of the term or terms for which any such patent(s) issue. Assignor hereby represents and warrants that Assignor has full right to convey its entire right, title, and interest in and to the Patents and Patent Applications herein assigned, and that Assignor has not executed and will not execute any agreement or other document in conflict therewith.

Assignor agrees to use its best efforts for as long as Assignor exists as a separate entity within the USMto effect such assignment, to execute and deliver separate Assignments, patent applications, and other documents necessary or expedient in connection with, and to cooperate with and to assist Assignee in connection with: further perfecting the assignment of the Patents and Patent Applications to Assignee; Assignee's preparation, filing, prosecution (including without limitation defense in interference proceedings, reexaminations, or litigation), enforcement, and/or maintenance of the Patents and Patent Applications; or for Assignee to protect and commercialize the intellectual property right, title, and interests in and to the Patents and Patent Applications (including without limitation copyright and/or trademarks).

Assignor agrees to use its best efforts for as long as Assignor exists as a separate entity within the USM to pay any direct costs incurred by or on behalf of Assignor prior to the Effective Date of this agreement in association with preparing, filing, prosecuting, enforcing, maintaining, or otherwise protecting the patents and patent applications identified in Exhibit A. Assignee shall not be liable for any

PATENT REEL: 024678 FRAME: 0822 such direct costs incurred by or on behalf of Assignor prior to the Effective Date of this agreement. Assignor shall incur no further costs as of the Effective Date of this agreement.

Assignor hereby requests that the Commissioner of Patents transfer registered ownership of said Patents and Patent Applications, and any reissuance or extension thereof, to the Assignee for the sole use and benefit of the Assignee, its successors, legal representatives and assigns.

ASSIGNOR:	ASSIGNEE:
UNIVERSITY OF MARYLAND BIOTECHNOLOGY INSTITUTE	UNIVERSITY OF MARYLAND BALTIMORE
By: Zavarl Essent	By: Ques L. Phr
Name: Edward Eisenstein Title:Acting President, UMBI  Date: OHOIIO	Name: Vames L. Hughes Vice President, Office of Research and Development  Date: 337(0)
Witness: Cynthin M. DIEFFEDBACH	Witness:
Witness: Canthia M. DIEFFENBACH	Witness: Sharing Tolor

4107061066

ORD

		defermen	e ineriilae(s)	Paterri tišle	Patent (in)	aleg Palls	Application Status	Patene Application No.	Issue Date	Date of Kin
04-Q28-PRV	E	Plyesoffacor Redfield	Redlield, Dr. Robert R.	USE OF INSTRUBING AND ITS OCIOVATIVES IN THE TREATMENT OF	INFELLECTUAL PROPERTY TECHNOLOGY LAW	9/3/2006	Refiled	63/606,999		- <del> </del>
N-OZS-PRV-2	# ·	Rediæld	Davis, Dr. Charles E. Jr. Hereda, Dr. Alanso Redfield, Dr. Robert R.	USE OF INDIRUBIN AND ITS DERIVATIVES IN THE TREASMENT OF 64'V NHE CHOW AND HEART FAILURE	ECHNORORA TWO BECHNORORA TWO BECHNORORA TWO	9/12/2005	Enley into National Phase 60/716,097	e 60/716,097		
	Ħ	Redfield	Davis, Dr. Charles E. Jr. Heredis, Dr. Atonso Reddield, Dr. Robert P.  Davis, Dr. Charles, E. Jr.	COMPOSITIONS FOR THEATMENT OF HIV INFECTACIN AND MICHORS THEREOF	NATIR WAY & BRICON	\$/11/2000	Entry Crito National Phase 09/037,652	09/637,652	·	·
99-001-PCT-AU	VHI	Rediield	Heredia, W. Atonso Rediteld, Dr. Robert R.	COMPOSITIONS FOR THEAT MENT OF HIM INVECTION AND METHODS THEREOF	MODRE & YAN ALLEN	3/7/2002	dspeed	66385/00	1/15/2004	765724
99-001-PCT-CA	MS.	Redlield	Davis, Dr. Charles (f. Jr. Heneda, Dr. Albosso Redfæld, Dr. Robert R.	TIONS FOR TREAT	MDORE & VAN ALLEN	2/12/2002	Jensi	2380924	2/19/2006	2380924
99-103-РСТ-ДР	Hg '	Redfland	Davis, Dr. Charles E. Jr. Heredia, Dr. Alonso Besthert, Pr. Bobert P.	TIONS FOR TREATMENT OF	MODEL & VEN WITEN	3/4/2002	Pending	5 750 54 034 5		
99-001-PC1-US	¥.	Redick	Davis, Dr. Charles E. Jr. Heredia, IV. Alcruso Redlield, Dr. Robert R.	THOMS FOR TREATMENT OF	NETTY NYA 'R BUCOM	6/14/2000	Isoled	09/637,652	13/11/2002	6,479,466
ABA-700-66	£ ,	Redlield	Davis, Dr. Charles E. Jr. Heredia, br. Alcoso Redileid, Dr. Robert A.	PIOYS FOR THEATMANT OF	MODRE & VAN ALIEN	8/13/1999	Converted to Nor-PRV	60/149,029		
99-012-05	¥	Resign	Davis, Dr. Charles E. Jr. Heredia, Dr. Afonso Refiz, Marvin Toulke, James S. Jr. Fouls Dr. Tenul he Hav				No Fatent Filings	. day 0M.		•

IMPERECTANT RECHARACTORY REDUCT.

THEOREM TATENT VARIATIONS REDUCT.

THEOREM TATENTAL VARIATIONS REDUCT.

**PATENT REEL: 024678 FRAME: 0824**